| Literature DB >> 25955567 |
Mariëtte R Boon1, Leontine E H Bakker, Rianne A D van der Linden, Antoinette F van Ouwerkerk, Pauline L de Goeje, Jacqueline Counotte, Ingrid M Jazet, Patrick C N Rensen.
Abstract
Cardiovascular disease (CVD) is the leading cause of death in modern society. Interestingly, the risk of developing CVD varies between different ethnic groups. A particularly high risk is faced by South Asians, representing over one-fifth of the world's population. Here, we review potential factors contributing to the increased cardiovascular risk in the South Asian population and discuss novel therapeutic strategies based on recent insights. In South Asians, classical ('metabolic') risk factors associated with CVD are highly prevalent and include central obesity, insulin resistance, type 2 diabetes, and dyslipidemia. A contributing factor that may underlie the development of this disadvantageous metabolic phenotype is the presence of a lower amount of brown adipose tissue (BAT) in South Asian subjects, resulting in lower energy expenditure and lower lipid oxidation and glucose uptake. As it has been established that the increased prevalence of classical risk factors in South Asians cannot fully explain their increased risk for CVD, other non-classical risk factors must underlie this residual risk. In South Asians, the prevalence of "inflammatory" risk factors including visceral adipose tissue inflammation, endothelial dysfunction, and HDL dysfunction are higher compared with Caucasians. We conclude that a potential novel therapy to lower CVD risk in the South Asian population is to enhance BAT volume or its activity in order to diminish classical risk factors. Furthermore, anti-inflammatory therapy may lower non-classical risk factors in this population and the combination of both strategies may be especially effective.Entities:
Keywords: Endothelial dysfunction; HDL dysfunction; inflammation; insulin resistance; type 2 diabetes
Mesh:
Year: 2015 PMID: 25955567 DOI: 10.3109/10408363.2014.1003634
Source DB: PubMed Journal: Crit Rev Clin Lab Sci ISSN: 1040-8363 Impact factor: 6.250